Given the steadily increasing request for precise molecular characterization of breast cancer to ensure correct patient management, we aimed to retrospectively evaluate our patient cohort for reproducibility of the biopsy results for ER, PR, c-erbB2, and Ki-67, focusing also on the recently defined ER-LP and HER2-low groups. The gene discussed is MKI67; the disease is breast carcinoma.